XMXun-Wu Meng

Xun-Wu Meng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xun-Wu Meng has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The analysis of missed diagnosis and misdiagnosis of 144 tumor-induced osteomalacia patients

    by Juan Feng, Yan Jiang, Ou Wang, Mei Li, Xiao-Ping Xing, Xun-Wu Meng, Weibo Xia

    Introduction: Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome which is usually induced by mesenchymal tissue tumor with excessive secretion of FGF23. The misdiagnosis of TIO is frequently seen in clinic. Therefore, this study is aimed to describe the misdiagnosed situation of TIO, explore the possible underlying reasons for missed diagnosis and misdiagnosis through the analysis of 144 TIO patients, and improve clinicians’ awareness of TIO. Methods: The clinical data of 144 surgically treated TIO patients in our hospital during December 1982–December 2014 were retrospectively analysed, including general information, clinical manifestation, laboratory examination, missed diagnosis and misdiagnosis. Results: 1. General Information. There were 80 male cases (55.6%) and 64 female cases (44.4%), with the onset age being 37.5±11.4 years old. The pathological type was mostly phosphate urinary mesenchymal tumor. After resection of the responsible neoplasm, 117 cases achieved serum phosphorus recovery. 2. The clinical manifestations of TIO mainly included bone pain (99%), difficulty in activity (93%), non-violent fractures (80%), muscle weakness (65%), shorter height (69%), thoracic deformity (33%) and spinal deformity (27%). Bone pain might be the initial symptom (92%). 3. Patients demonstrated low serum phosphorus (0.48±0.13 mmol/l), decreased tubular maximum of phosphate/glomerular filtration rate (TMP/GFR)(0.40±0.17), elevated serum alkaline phosphatase (282.6±161.0 U/l). 4. Missed diagnosis and misdiagnosis analysis. The clinic departments TIO patients referred to mainly distributed in endocrinology (35%), orthopedics (26%), rheumatology (23%), neurology (8%). The misdiagnosis rate was 95%. TIO was frequently misdiagnosed as intervertebral disc herniation (46 case-time), spinal arthritis (including ankylosing spondylitis) (38 case-time), osteoporosis (37 case-time), and other diseases including arthritis, femoral head necrosis, hyperparathyroidism, etc. The missed diagnosis rate of hypophosphatemia was high (43%). Conclusions: TIO is a vital cause of adult-onset hypophosphatemia in China, but clinicians generally lack awareness and knowledge of this disease. Consequently, the misdiagnosed rate of TIO is high. Therefore, clinicians should further enhance their recognition of TIO and pay attention to searching for tumor in adult-onset patients with hypophosphatemic osteomalacia.


  • Mutation update and short-term outcome after treatment with active vitamin D3in Chinese patients with pseudo-vitamin D-deficiency rickets

    by Yue Chi, Jing Sun, Li Pang, Ruizhi Jiajue, Yan Jiang, Ou Wang, Mei Li, Xiaoping Xing, Yingying Hu, Xueying Zhou, et al.

    Pseudovitamin D-deficiency rickets (PDDR) is a rare autosomal recessive disorder resulting from a defect in renal 25-hydroxyvitamin D 1α-hydroxylase, which is encoded by the CYP27B1 gene. To our best knowledge, 48 mutations of the CYP27B1 gene have been identified so far. In the present study, we investigated CYP27B1 mutations in seven individuals from six separate families and identified nine different mutations: two novel missense mutations (G194R, R259L), three novel and one reported deletion mutations (c1446delA, c1504delA, c311-321del and c. 48-60del), two novel nonsense mutations (c.85G>T, c.580G>T) and 1 reported insertion mutation (c1325-1332insCCCACCC). Our findings enriched the database of CYP27B1 mutations. To investigate the response to short-term treatment with calcitriol in PDDR patients, we additionally collected clinical data of eight PDDR patients from our previous study and analyzed the changes of clinical manifestations and biochemical parameters after treated with calcitriol in the whole 15 patients. The statistical analysis revealed that serum ALP and PTH significantly decreased after 6-month treatment with calcitriol. The height change of the patients is positively related to the duration of the treatment (r=0.772, P=0.009), which implicated the importance of long-term calcitriol supplementation for the growth development of children with PDDR.

  • Evaluation of targeted next-generation sequencing in diagnosis of Chinese adult-onset idiopathic hypoparathyroidism

    by Yuepeng Li, Ou Wang, Tingting Quan, Xueying Chu, Weibo Xia, Mei Li, Yan Jiang, Xunwu Meng, Xiaoping Xing

    Objectives: Several genes have been recognized to be associated with nonsurgical hypoparathyroidism. Most previous studies focused on gene mutation among paediatric hypoparathyroidism patients. Data about gene mutations in adult-onset hypoparathyroidism patients is still lacking. This study was designed to evaluate the role of gene defects in the pathogenesis of adult-onset hypoparathyroidism in China through the targeted next-generation sequencing (NGS). Subjects and methods: We recruited 17 patients with adult-onset nonsurgical hypoparathyroidism who were regularly followed or newly diagnosed at our centre during the past one year. Nine of them developed hypercalciuria during the treatment with calcium and vitamin D agents. None of them had physical deformity or family history of hypoparathyroidism. Targeted NGS was performed to screen 10 related genes, including AIRE, AP2S1, CASR, CLDN16, FAM111A, GATA3, GCM2, PTH, TBCE and TRPM6. Results: A novel homozygosis mutation of GCMB gene [c.130G>A (p.G44S)] was identified which was predicted to be deleterious by PolyPhen2. The patient was a 36-year-old woman who suffered from paroxysmal carpopedal spasms in the menstrual cycle for ten years. Before treatment, the serum calcium and phosphorus was 1.48 mmol/l and 2.29 mmol/l, respectively. And the PTH concentration was lower than 3.0 pg/ml. intracranial calcification and cataract were also identified. During treatment with calcium and vitamin D, she developed hypercalciuria when her serum calcium reached 2.04 mmol/l. Hydrochlorothiazide was administered. No evidence of urolithiasis was found. Conclusions: In this study, we identified the genetic defect only in 1 patient (5.9%). In adult-onset nonsurgical hypoparathyroidism without other diagnostic clues, the gene mutation screening as the first choice to clarify the aetiology was not recommended.

  • Clinical features and targeted gene sequencing analysis of paediatric hypoparathyroidism

    by Yuepeng Li, Ou Wang, Tingting Quan, Xueying Chu, Weibo Xia, Mei Li, Yan Jiang, Xunwu Meng, Xiaoping Xing

    Objectives: For paediatric patients with hypoparathyroidism, genetic defects should be considered firstly. This study was to investigate the clinical features and analyse gene mutations of Chinese patients with child-onset hypoparathyroidism. Subjects and methods: We enrolled 35 paediatric patients with hypoparathyroidism at our clinical centre between 1984 and 2014. Clinical characteristics were collected and Targeted next-generation sequencing (NGS) was performed to test ten related gene mutations, including AIRE, AP2S1, CASR, CLDN16, FAM111A, GATA3, GCM2, PTH, TBCE and TRPM6. Results: The average age of onset was 8.7 years. There were 33 patients (94.3%) with tetany and 22 patients (62.9%) with seizures at the first visit. Before treatment, the average serum calcium and phosphorus were 1.65±0.34 mmol/l and 2.40±0.53 mmol/l, respectively. And the median PTH concentration was 3.0 pg/ml (range 1.0–9.8). Intracranial calcification was identified in 30 out of 31 patients (96.8%), nine in 11 patients who had made ophthalmologic consultation were diagnosed as cataract. And 11 patients had hypercalciuria. We identified 6 patients (17.1%) with gene defects, including four patients with deletion mutation of TBX1 and COMT gene, one patient with a novel GATA3 mutation (c.286delT; p.W96Gfs*99), and a known mutation of CASR gene in a family. Conclusions: The current study suggests that it is necessary to monitoring the complications of hypoparathyroidism, such as hypercalciruia, renal damage and basal ganglia calcification. For paediatric patients, gene testing should be conducted to clarify the aetiology.

  • Clinical characterization and genetic analysis of TRPV4-related skeletal dysplasias in 4 Chinese families

    by Yue Chi, Qianqian Pang, Lijun Xu, Yan Jiang, Mei Li, Ou Wang, Xiaoping Xing, Xunwu Meng, Xueying Zhou, Weibo Xia

    TRPV4-associated skeletal dysplasias include: FDAB, ADBO, SMDK, SEDM, MD and Parastremmatic dysplasia. In this study, we recruited 3 families with congenital scoliosis and 1 family with localized digital osteopetrosis. We collected their clinical data and use the next-generation sequencing system, Sanger sequencing and RT-PCR to obtain the genetic diagnosis. Proband 1, 2, 3 all presented with early-onset kyphoscoliosis and short stature. X-ray showed platyspondyly, hemivertebra, accompanied by metaphyseal abnormalities. P1 also presented with waddling gait, bilateral streblomicrodactyly, P2 with bended upper arm and genu valgum, P3 with left femoral head subluxation. Bone turnover markers were normal. P4 presenteed with right phalanges thickening after frostbite. P4 and her mother also presented with shortening of the toes and teeth loss. X-ray showed cortical bone thickening. Two mutations of TRPV4 have been identified: Proband 1, 2, 3 were all heterozygous for c.1781G>A, a hot-spot mutation of SMDK. Proband 4 and her mother were heterozygous for a novel splice-site mutation c.1491+1G>A, and was proved to lead to skipping of exon 8 in the transcript. We firstly reported the SMDK and FDAB cases in the Chinese population. The three SMDK families carrying the same missense mutation R594H implicated that R594H may be a hot-spot mutation in Chinese. The novel splice-site mutation found in the FDAB family, is the first reported splice-site mutation of TRPV4 gene.

  • MEN1 c.825-1G>A mutation in a family with multiple endocrine neoplasia type 1: A case report

    by Zhiwei Ning, Ou Wang, Xunwu Meng, Xiaoping Xing, Weibo Xia, Yan Jiang, Mei Li, Yuan Xu

    Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease characterized by combined occurrence of tumors and hyperplasia in tissues including the parathyroid, gastrointestinal endocrine tissue and anterior pituitary. Heterozygous germline mutation of the tumor suppressor gene MEN1 is the cause of the disease. Treatment and long‑term follow up of patients with MEN1 are rarely reported in the literature due to the relative rarity of the disease; thus, there is limited understanding of tumor biology and behavior, and heterogeneous clinical presentation. This case report observed a family that presented with MEN1 c.825‑1G>A mutation. The clinical features and treatment were followed up for >20 years. Detailed family history of this pedigree was investigated and followed up. Genomic DNA was extracted by standard methods from peripheral leukocytes. The coding sequence, including 9 coding exons and 16 splice junctions of the MEN1 gene of leukocyte DNA was determined. The proband presented with gastrinoma, pituitary tumors, hyperparathyroidism, thymoma and lung carcinoid tumors, and was followed from age 35 to 54 years old. During the 20 years, the patient underwent four surgeries: Trans‑sphenoidal adenomectomy, followed by post operative radiotherapy at 39 years; hyperplasia parathyroid gland resection at 40 years; removal of pancreatic, head and neck, duodenal, gallbladder, bile duct, subtotal gastric (4/5) and pyloric region lymph nodes at age 41; and a thymectomy and left lung carcinoid tumor removal procedure at the age of 49. The patient died of unrelated trauma and had a relatively stable illness course. DNA sequence analysis revealed MEN1 gene c.825‑1G>A or IVS 5‑1G>A mutation in the family. Two carriers in the pedigree were identified and followed up. Data indicated that although MEN1 is a complex disease involving multiple organs and systems, MEN1 tumors should be considered surgically curable. If patients are properly cared for by multidisciplinary teams comprising of relevant specialists with experience in the diagnosis and treatment of patients with endocrine tumors, patients may have a relatively positive prognosis.


  • Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones

    by Hai Wang, Dingrong Zhong, Yong Liu, Yan Jiang, Guixing Qiu, Xisheng Weng, Xiaoping Xing, Mei Li, Xunwu Meng, Fang Li, et al.

    Tumor-induced osteomalacia is a rare and fascinating paraneoplastic syndrome usually caused by a small, benign phosphaturic mesenchymal tumor. Most tumors are treated surgically, but we are unaware of any reports that compare the results of curettage and segmental resection for lesions in long bones. Seventeen patients (ten male and seven female) with tumor-induced osteomalacia lesions in long bones, who underwent surgical treatment from December 2004 to August 2013 in our hospital, were included in this retrospective study. The mean follow-up (and standard deviation) was 35 ± 27 months (range, twelve to 116 months). The characteristics of the tumor and the effects of different surgical treatments (curettage compared with segmental resection) were evaluated. All patients showed typical clinical characteristics of tumor-induced osteomalacia, including elevated serum fibroblast growth factor-23 (FGF-23); 82% of tumors were in the epiphysis, and 82% grew eccentrically. The mean maximum diameter of the tumors was 2.4 ± 2.0 cm. The complete resection rates were similar for curettage (67%) and segmental resection (80%). However, the recurrence rate after curettage (50%) was higher than that after segmental resection (0%). The complete resection rate for secondary segmental resection (75%) was not different from that for primary segmental resection (83%). All of our cases of tumor-induced osteomalacia were caused by phosphaturic mesenchymal tumors. After successful removal of tumors, serum FGF-23 returned to normal within twenty-four hours and serum phosphorus levels returned to normal at a mean of 6.5 ± 3.5 days. Most lesions in long bones are located in the epiphysis, so curettage is first suggested to maintain joint function. If curettage is incomplete or there is a recurrence, secondary segmental resection should be considered curative. Changes of serum FGF-23 and phosphorus levels before and after the operation may be of prognostic help. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.


    • 12 November 2013
      • Vol. 93  (42) , 3364-8

    [CDC73 gene mutation and parafibromin expression status of parathyroid carcinoma in Chinese].

    by Jing Kong, Ou Wang, Min Nie, Jie Shi, Yan Jiang, Mei Li, Wei-Bo Xia, Xun-Wu Meng, Xiao-Ping Xing

    To explore the clinico-genetic characteristics and protein status of parathyroid carcinoma (PC) diagnosed at Peking Union Medical College Hospital from January 1980 to December 2012. Genomic DNA was extracted from peripheral blood lymphocytes and paraffin-embedded tissue for analysis. The mutations of CDC73 gene were detected by direct sequencing. And the expression of parafibromin in tumor tissues was evaluated by immunohistochemical analysis. Twenty-four PC patients were recruited. The mean ages at the diagnosis of PHPT and PC were 42.2 and 42.6 years respectively. The serum calcium at the diagnosis of PHPT was 3.78 mmol/L, serum phosphorus 0.65 mmol/L and the median increment of serum parathyroid hormone (PTH) level 20.0. The recurrent rate was 76.2% during a 5-year follow-up.Genetic analysis identified 11 mutations of CDC73 gene (45.8%), among which c.34_35 insCT, c.626_629 delAACA, c.260_261 delGA, c.570 delG, c.40 C>T and IVS3+1 G>A were novel mutation first identified in our cohort. Nine of them had germline mutations. All tissue samples from normal parathyroid displayed strong positive immunostaining of parafibromin. Complete (55%, 11/20) or partial (45%, 9/20) loss of parafibromin expression was observed in PC tissues. The age at the diagnosis of PHPT, serum calcium, serum phosphorus, PTH, alkaline phosphatase (ALP), bone involvement rate, kidney stone/calcification rate, recurrent rate, metastatic rate and immunostaining level showed no significant difference between the patients with and without CDC73 mutation. In Chinese population, CDC73 mutation and complete/partial loss of immunohistochemical staining for parafibromin occur frequently in PC. Therefore it may be useful in the subset of tumors with equivocal histological examination.


    • 1 August 2012
      • Vol. 125  (16) , 2895-901

    Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.

    by Ou Wang, Chun-Yan Wang, Jie Shi, Min Nie, Wei-Bo Xia, Mei Li, Yan Jiang, Heng Guan, Xun-Wu Meng, Xiao-Ping Xing

    It is widely recognized that the diagnosis of parathyroid carcinoma (PC) is often difficult because of the overlap of characteristics between malignant and benign parathyroid tumors, especially at an early stage. Our study aimed to investigate the differential expression of Ki-67, galectin-3, fragile histidine triad (FHIT) gene, and parafibromin in PC, parathyroid adenoma (PA), parathyroid hyperplasia (PH), and normal parathyroid (NP) tissues; then to assess these expression values for use in differential diagnosis of malignant and benign parathyroid tumors. Data of 15 cases with PC, 19 PAs, and 8 PHs were retrospectively analyzed for their clinical characteristics. The expression of Ki-67, galectin-3, FHIT, and parafibromin were detected via immunohistochemistry in the above-mentioned specimens and 6 NPs as control. Complete loss of parafibromin expression was seen in 9 of 15 (60%) carcinomas, and all normal parathyroid tissues and parathyroid benign tumors stained positive for parafibromin except for one (4%) adenoma. Galectin-3 staining was positive in 11 of 15 (73%) carcinomas, 5 of 19 (26%) adenomas, 1 of 8 (12%) hyperplasias, and 0 of 6 normal tissues. The Ki-67 proliferative index was high in 4 of 15 (27%) carcinomas, 1 of 19 (5%) adenomas, and none of the hyperplasia or normal tissues. FHIT expression did not differ appreciably among the tumor types. The combination of overexpression of galectin-3 or loss of parafibromin increased sensitivity for PC to 87%, while the specificity of both positive galectin-3 and positive Ki-67 could reach 100%. These data suggested that loss of parafibromin and overexpression of galectin-3 and Ki-67 might help to distinguish parathyroid carcinoma from other parathyroid tumors. And the combination of two or three of these markers might produce better sensitivity and/or specificity for the diagnosis of parathyroid carcinoma.


  • Open Access

    Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature

    by Yan Jiang, Wei-Bo Xia, Xiao-Ping Xing, Barbara C Silva, Mei Li, Ou Wang, Hua-Bing Zhang, Fang Li, Hong-Li Jing, Ding-Rong Zhong, et al.

    Tumor‐induced osteomalacia (TIO) is an acquired form of hypophosphatemia. Tumor resection leads to cure. We investigated the clinical characteristics of TIO, diagnostic methods, and course after tumor resection in Beijing, China, and compared them with 269 previous published reports of TIO. A total of 94 patients with adult‐onset hypophosphatemic osteomalacia were seen over a 6‐year period (January, 2004 to May, 2010) in Peking Union Medical College Hospital. After physical examination (PE), all patients underwent technetium‐99m octreotide scintigraphy (99Tcm‐OCT). Tumors were removed after localization. The results demonstrated that 46 of 94 hypophosphatemic osteomalacia patients had high uptake in 99Tcm‐OCT imaging. Forty of them underwent tumor resection with the TIO diagnosis established in 37 patients. In 2 patients, the tumor was discovered on PE but not by 99Tcm‐OCT. The gender distribution was equal (M/F = 19/20). Average age was 42 ± 14 years. In 35 patients (90%), the serum phosphorus concentration returned to normal in 5.5 ± 3.0 days after tumor resection. Most of the tumors (85%) were classified as phosphaturic mesenchymal tumor (PMT) or mixed connective tissue variant (PMTMCT). Recurrence of disease was suggested in 3 patients (9%). When combined with the 269 cases reported in the literature, the mean age and sex distribution were similar. The tumors were of bone (40%) and soft tissue (55%) origins, with 42% of the tumors being found in the lower extremities. In summary, TIO is an important cause of adult‐onset hypophosphatemia in China. 99Tcm‐OCT imaging successfully localized the tumor in the overwhelming majority of patients. Successful removal of tumors leads to cure in most cases, but recurrence should be sought by long‐term follow‐up. © 2012 American Society for Bone and Mineral Research.